In Reply Drs Luo and Kesselheim raise some relevant concerns regarding our Viewpoint on the IOM report entitled Delivering High-Quality Cancer Care: Charting a Course for a System in Crisis.1 Luo and Kesselheim recognize and share our concern regarding the underrepresentation of older adults in clinical trials. However, they disagree with the committee’s recommendation regarding amending patent law to provide patent exclusivity extension for companies conducting clinical trials in older adults for drugs to be used in that population, and suggest some alternative strategies.
Cohen HJ, Naylor M, Hurria A. Underrepresentation of Older Adults in Cancer Trials—Reply. JAMA. 2014;311(9):966-967. doi:10.1001/jama.2013.286457